Kailun Gao, Ying Wu, Yan Zhang, Pei Dang, Huanjia Xue, Teng Li, Meiyan Zhou, Liwei Wang, Yangzi Zhu
{"title":"Alpha-lipoic acid alleviates oxidative stress and brain damage in patients with sevoflurane anesthesia.","authors":"Kailun Gao, Ying Wu, Yan Zhang, Pei Dang, Huanjia Xue, Teng Li, Meiyan Zhou, Liwei Wang, Yangzi Zhu","doi":"10.3389/fphar.2025.1572156","DOIUrl":null,"url":null,"abstract":"<p><p>Sevoflurane, the most commonly used inhalational anesthetic, may negatively impact the brain by inducing oxidative stress. This study investigated the potential protective role of alpha-lipoic acid (ALA) in mitigating sevoflurane-induced oxidative stress and brain damage. A total of 155 patients undergoing sevoflurane anesthesia for liver resection surgery were randomly assigned to receive either ALA or a placebo. Perioperative internal jugular venous blood samples were collected to measure oxidative stress markers (8-OHdG, sORP, and cORP) and brain injury biomarkers (S100β and UCH-L1). Postoperative cognitive function was also evaluated. The results demonstrated that, compared to the placebo group, the ALA group exhibited a significant reduction in 8-OHdG levels by 0.007 nmol/L (95% CI, -0.011 to -0.003; P = 0.03) 24 h after surgery, accompanied by lower sORP levels and higher cORP levels. Furthermore, postoperative levels of S100β and UCH-L1 were significantly lower in the ALA group than in the placebo group (S100β, P = 0.02; UCH-L1, P = 0.03). Additionally, oxidative stress markers were significantly correlated with brain damage 24 h after surgery. Our findings suggest that ALA significantly reduces sevoflurane-induced oxidative stress and brain damage, while also improving postoperative cognitive function, indicating its potential neuroprotective effect. <b>Clinical Trial Registration:</b> https://www.chictr.org.cn/, identifier ChiCTR2300077321.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1572156"},"PeriodicalIF":4.4000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965138/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2025.1572156","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Sevoflurane, the most commonly used inhalational anesthetic, may negatively impact the brain by inducing oxidative stress. This study investigated the potential protective role of alpha-lipoic acid (ALA) in mitigating sevoflurane-induced oxidative stress and brain damage. A total of 155 patients undergoing sevoflurane anesthesia for liver resection surgery were randomly assigned to receive either ALA or a placebo. Perioperative internal jugular venous blood samples were collected to measure oxidative stress markers (8-OHdG, sORP, and cORP) and brain injury biomarkers (S100β and UCH-L1). Postoperative cognitive function was also evaluated. The results demonstrated that, compared to the placebo group, the ALA group exhibited a significant reduction in 8-OHdG levels by 0.007 nmol/L (95% CI, -0.011 to -0.003; P = 0.03) 24 h after surgery, accompanied by lower sORP levels and higher cORP levels. Furthermore, postoperative levels of S100β and UCH-L1 were significantly lower in the ALA group than in the placebo group (S100β, P = 0.02; UCH-L1, P = 0.03). Additionally, oxidative stress markers were significantly correlated with brain damage 24 h after surgery. Our findings suggest that ALA significantly reduces sevoflurane-induced oxidative stress and brain damage, while also improving postoperative cognitive function, indicating its potential neuroprotective effect. Clinical Trial Registration: https://www.chictr.org.cn/, identifier ChiCTR2300077321.
期刊介绍:
Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.